First-year costs of treating prostate cancer: Estimates from SEER-Medicare data

Claus Roehrborn, P. Albertsen, M. E. Stokes, L. Black, A. Benedict

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13091, prevention strategies have the potential to reduce health-care costs.

Original languageEnglish (US)
Pages (from-to)355-360
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume12
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Medicare
Prostatic Neoplasms
Costs and Cost Analysis
Health Care Costs
Economics
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

First-year costs of treating prostate cancer : Estimates from SEER-Medicare data. / Roehrborn, Claus; Albertsen, P.; Stokes, M. E.; Black, L.; Benedict, A.

In: Prostate Cancer and Prostatic Diseases, Vol. 12, No. 4, 2009, p. 355-360.

Research output: Contribution to journalArticle

Roehrborn, Claus ; Albertsen, P. ; Stokes, M. E. ; Black, L. ; Benedict, A. / First-year costs of treating prostate cancer : Estimates from SEER-Medicare data. In: Prostate Cancer and Prostatic Diseases. 2009 ; Vol. 12, No. 4. pp. 355-360.
@article{c9141b4a677949b99ed07f09449e235d,
title = "First-year costs of treating prostate cancer: Estimates from SEER-Medicare data",
abstract = "Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13091, prevention strategies have the potential to reduce health-care costs.",
author = "Claus Roehrborn and P. Albertsen and Stokes, {M. E.} and L. Black and A. Benedict",
year = "2009",
doi = "10.1038/pcan.2009.21",
language = "English (US)",
volume = "12",
pages = "355--360",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - First-year costs of treating prostate cancer

T2 - Estimates from SEER-Medicare data

AU - Roehrborn, Claus

AU - Albertsen, P.

AU - Stokes, M. E.

AU - Black, L.

AU - Benedict, A.

PY - 2009

Y1 - 2009

N2 - Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13091, prevention strategies have the potential to reduce health-care costs.

AB - Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13091, prevention strategies have the potential to reduce health-care costs.

UR - http://www.scopus.com/inward/record.url?scp=70749111420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70749111420&partnerID=8YFLogxK

U2 - 10.1038/pcan.2009.21

DO - 10.1038/pcan.2009.21

M3 - Article

C2 - 19468284

AN - SCOPUS:70749111420

VL - 12

SP - 355

EP - 360

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -